Pantoprazole Eg (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazole Eg, is a proton pump inhibitor presented as a tablet for oral use. It treats acid‑related stomach and esophageal conditions in adults and children where reduction of gastric acidity is required.

GNH USA supplies Pantoprazole Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole Eg is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑oesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of erosive esophagitis. - Erosive gastritis and duodenal ulcer disease: supports ulcer healing by maintaining a higher gastric pH. - Zollinger‑Ellison syndrome: controls gastric hypersecretion associated with gastrin‑producing tumours. - Prevention of NSAID‑induced gastric ulcers: lowers ulcer risk in patients requiring long‑term non‑steroidal anti‑inflammatory therapy.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually transient. - Nausea or abdominal discomfort: may improve with continued use. - Flatulence: occasional gas buildup. - Constipation: infrequent but reported.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile‑associated diarrhoea: persistent watery stools. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: abnormal liver function tests.

When prescribing Pantoprazole Eg, clinicians should consider several safety aspects: - Assess renal and hepatic function: dose adjustment may be required in severe impairment. - Review concomitant medications: potential for drug‑drug interactions, especially with drugs needing acidic pH for absorption. - Monitor long‑term users: watch for magnesium deficiency, bone health, and possible infections. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Pediatric use: reserve for approved age groups and indications. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Pantoprazole Eg can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir, nelfinavir): reduced absorption and efficacy. - Antifungal agents (e.g., ketoconazole, itraconazole): markedly decreased bioavailability. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, requiring more frequent monitoring. - Methotrexate: reduced renal clearance may raise serum levels. - Digoxin: slight increase in serum concentration. - Iron salts and certain oral bisphosphonates: decreased absorption; separate dosing by at least 2 hours.